1. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–8.
2. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77.
3. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.
4. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–8.
5. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
6. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828–40.
7. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
8. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.
9. ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (2-й пересмотр). Кардиоваск. тер. и проф. 2008; Прил. 4.
10. ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр). Кардиоваск. тер. и проф. 2008. Прил. 4.
11. Руда М.Я., Голицын С.П., Грацианский Н.А. и др. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Кардиоваск. тер. и проф. 2007; 6 (8): Прил. 1.
12. Bots ML, Remme WJ, Luscher TF et al. ACE inhibition and endothelial function: mail findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007; 21: 269–79.
13. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol. 2007; 100: 159–63
14. Ceconi C, Fox K, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
15. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM et al. Coronary artery remodeling is related to plaque composition. Heart. 2006; 92: 388–91.
16. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-dependent and independent effect of agents that inhibit renin-angiotensin systen. Hypertens 2007; 25: 951–8.
17. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different regiment to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomized trials. BMJ 2008; 336: 1121-3.
18. Ferrari R, Pasanisi G, Notarstefano P et al. Specific properties and effect of perindopril in controlling the rennin-angiotensin system. Am J Hypertens 2005; 18: 1425–45.
19. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Hypertens Journal 2006; 27.
20. Карпов ЮА. Ренин-ангиотензиновая система сосудистой стенки как мишень для терапевтических вмешательств. Кардиология 2003; 5: 97–101.
21. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6.
22. Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drug Ther 2007; 21: 423–9.
23. Zhuo JL, Froomes P, Casley D et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997; 96 (1): 174–82.
24. Brugts JJ, Ninomiya T, Boersma E. The consistency of the treatment effect of an ACE-ingibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009; 30: 1385–94.

Ю.А.Карпов